AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).
AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback